268 related articles for article (PubMed ID: 37622116)
81. A novel ferroptosis-related gene signature for prognostic prediction of patients with lung adenocarcinoma.
Jin J; Liu C; Yu S; Cai L; Sitrakiniaina A; Gu R; Li W; Wu F; Xue X
Aging (Albany NY); 2021 Jun; 13(12):16144-16164. PubMed ID: 34115610
[TBL] [Abstract][Full Text] [Related]
82. Development of a ferroptosis-based model to predict prognosis, tumor microenvironment, and drug response for lung adenocarcinoma with weighted genes co-expression network analysis.
Cheng T; Shan G; Yang H; Gu J; Lu C; Xu F; Ge D
Front Pharmacol; 2022; 13():1072589. PubMed ID: 36467089
[No Abstract] [Full Text] [Related]
83. A novel cuproptosis-related gene model predicts outcomes and treatment responses in pancreatic adenocarcinoma.
Liu Q; Li R; Wu H; Liang Z
BMC Cancer; 2023 Mar; 23(1):226. PubMed ID: 36894917
[TBL] [Abstract][Full Text] [Related]
84. A ferroptosis-related gene signature predicts overall survival in patients with lung adenocarcinoma.
Gao X; Tang M; Tian S; Li J; Liu W
Future Oncol; 2021 Apr; 17(12):1533-1544. PubMed ID: 33432837
[TBL] [Abstract][Full Text] [Related]
85. Deep learning reveals cuproptosis features assist in predict prognosis and guide immunotherapy in lung adenocarcinoma.
Li G; Luo Q; Wang X; Zeng F; Feng G; Che G
Front Endocrinol (Lausanne); 2022; 13():970269. PubMed ID: 36060936
[TBL] [Abstract][Full Text] [Related]
86. Development and Validation of a Robust Ferroptosis-Related Prognostic Signature in Lung Adenocarcinoma.
Zhang A; Yang J; Ma C; Li F; Luo H
Front Cell Dev Biol; 2021; 9():616271. PubMed ID: 34249899
[TBL] [Abstract][Full Text] [Related]
87. Cross-talk between cuproptosis and ferroptosis regulators defines the tumor microenvironment for the prediction of prognosis and therapies in lung adenocarcinoma.
Shen Y; Li D; Liang Q; Yang M; Pan Y; Li H
Front Immunol; 2022; 13():1029092. PubMed ID: 36733399
[TBL] [Abstract][Full Text] [Related]
88. In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma.
Wang Y; Huang X; Chen S; Jiang H; Rao H; Lu L; Wen F; Pei J
Curr Oncol; 2022 Sep; 29(9):6573-6593. PubMed ID: 36135086
[TBL] [Abstract][Full Text] [Related]
89. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.
Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H
Front Immunol; 2022; 13():933241. PubMed ID: 36211378
[TBL] [Abstract][Full Text] [Related]
90. A Novel Prognostic Signature Revealed the Interaction of Immune Cells in Tumor Microenvironment Based on Single-Cell RNA Sequencing for Lung Adenocarcinoma.
Jin X; Hu Z; Sui Q; Zhao M; Liang J; Liao Z; Zheng Y; Wang H; Shi Y
J Immunol Res; 2022; 2022():6555810. PubMed ID: 35812244
[TBL] [Abstract][Full Text] [Related]
91. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
Chen X; Hu G; Xiong L; Xu Q
Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
[No Abstract] [Full Text] [Related]
92. Bioinformatics construction and experimental validation of a cuproptosis-related lncRNA prognostic model in lung adenocarcinoma for immunotherapy response prediction.
Li L; Cai Q; Wu Z; Li X; Zhou W; Lu L; Yi B; Chang R; Zhang H; Cheng Y; Zhang C; Zhang J
Sci Rep; 2023 Feb; 13(1):2455. PubMed ID: 36774446
[TBL] [Abstract][Full Text] [Related]
93. Pan-cancer analysis of cuproptosis-promoting gene signature from multiple perspectives.
Ma J; Gong B; Zhao Q
Clin Exp Med; 2023 Dec; 23(8):4997-5014. PubMed ID: 37318649
[TBL] [Abstract][Full Text] [Related]
94. Identification and validation of a novel cuproptosis-related genes signature associated with prognosis, clinical implications and immunotherapy of hepatocellular carcinoma.
He F; Zeng P; Ma S; Yang X; Liu H; Liu Q; Zhou Y; Zhu H
Front Pharmacol; 2023; 14():1088993. PubMed ID: 36843949
[No Abstract] [Full Text] [Related]
95. Cuproptosis-related LncRNAs are potential prognostic and immune response markers for patients with HNSCC via the integration of bioinformatics analysis and experimental validation.
Zhou L; Cheng Q; Hu Y; Tan H; Li X; Wu S; Zhou T; Zhou J
Front Oncol; 2022; 12():1030802. PubMed ID: 36620545
[TBL] [Abstract][Full Text] [Related]
96. Machine learning- and WGCNA-mediated double analysis based on genes associated with disulfidptosis, cuproptosis and ferroptosis for the construction and validation of the prognostic model for breast cancer.
Xu L; Wang S; Zhang D; Wu Y; Shan J; Zhu H; Wang C; Wang Q
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16511-16523. PubMed ID: 37712959
[TBL] [Abstract][Full Text] [Related]
97. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes.
Li F; Niu Y; Zhao W; Yan C; Qi Y
Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857
[TBL] [Abstract][Full Text] [Related]
98. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
[TBL] [Abstract][Full Text] [Related]
99. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.
Wu Y; Li K; Liang S; Lou X; Li Y; Xu D; Wu Y; Wang Y; Cui W
Respir Res; 2023 May; 24(1):142. PubMed ID: 37259066
[TBL] [Abstract][Full Text] [Related]
100. The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma.
Zhang L; Di L; Liu J; Lei X; Gu M; Zhang W; Wang Y
Front Genet; 2023; 14():1039813. PubMed ID: 36755568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
